Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets

Our plain-English summary of Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets, by I. Cavallari, F. Cerciello, E. Giovannetti, et al (Frontiers in Oncology, 2023).

The study

• Authors: I. Cavallari, F. Cerciello, E. Giovannetti, L. Urso
• Journal: Frontiers in Oncology
• Published: 2023;13:1163144
• Type of article: Editorial
• Read it: PubMed · Publisher · Free full text

In plain English

This was an editorial, not a research study. It introduced a collection of articles in Frontiers in Oncology on malignant pleural mesothelioma (MPM) and reported no new data of its own. As background, the authors named asbestos as the major cause of MPM. Citing other work, they said incidence is rising worldwide while treatment has advanced slowly. They argued that dedicated data repositories and bioinformatic tools are rare for this rare cancer. The editorial then described the collected articles. According to the editorial, Sato et al. found in MPM cell lines that overexpression of thymidylate synthase (TYMS) gave resistance to the drug pemetrexed, and that resistant cells had less dUMP and more dTMP. Huo et al. used a public dataset and reported that MPM tumors overexpress TWF1 and that higher expression was related to worse prognosis. Martens et al. described a group effort to build a first molecular pathway model of MPM. Two further articles described clinical questions where large dataset approaches may help, such as telling MPM apart from other diseases and recognizing people at hereditary risk. The authors concluded that bioinformatics strategies and dedicated data repositories are becoming crucial in MPM.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Editorial introducing a Research Topic (a collection of articles); no original data
• Who was studied: No study population; the editorial describes research articles on malignant pleural mesothelioma collected in a Frontiers in Oncology Research Topic
• Exposure: No exposure was studied; asbestos is named only as background, as the major cause of MPM
• Main results:
  • As reported by the editorial (finding of Sato et al., not of this editorial): in MPM cell lines, overexpression of TYMS conferred resistance to pemetrexed (PMX)
  • As reported by the editorial (Sato et al.): PMX-resistant cells showed reduced dUMP and increased dTMP, which the editorial said suggests dTMP as a possible additional biomarker
  • As reported by the editorial (Huo et al., using a public TCGA dataset): MPM tumors overexpress TWF1, and higher expression is related to worse prognosis
  • As reported by the editorial (Martens et al.): a group of experts established a first version of a molecular pathway model of MPM
  • As reported by the editorial (Usada et al. and Idkedek et al.): examples of clinical questions where large dataset approaches could help, such as distinguishing MPM from confounding diseases and recognizing individuals at hereditary risk
• The authors' conclusion: The authors concluded that bioinformatics strategies and dedicated data repositories are becoming crucial for analyzing and interpreting data in MPM, and that the Research Topic aims to give an overview of MPM focused on new potential biomarkers and research strategies drawn from omics studies

Topics

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma, Biomarker.

Related studies

• Editorial: Advances in malignant pleural mesothelioma: Diagnosis, treatment, and molecular mechanisms — M.G. Mastromarino, V. Aprile, et al. (2023)
• Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC — F. Facchinetti, A. Marabelle, et al. (2016)
• Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect — S. Golfier, C. Kopitz, et al. (2014)
• Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets — L.R. Motadi, N.L. Misso, et al. (2007)
• Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets — O.D. Røe, E. Anderssen, et al. (2010)
• Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours — Y. Chen, Z. Gao, et al. (2024)

Browse more research in Frontiers in Oncology, or return to medical research.